Exelixis (EXEL) Total Liabilities (2010 - 2026)
Exelixis (EXEL) posted quarterly Total Liabilities of $657.8 million for Q2 2026, down 6.85% year-over-year from $706.2 million in Q2 2025, and down 3.7% quarter-over-quarter from $683.1 million in Q1 2026.
Analysis
Exelixis (EXEL) Total Liabilities (2010 - 2026) Analysis & Trends
Exelixis' Total Liabilities history runs 17 years deep, the most recent figure standing at $657.8 million for Q2 2026.
- In Q2 2026, Total Liabilities fell 6.85% year-over-year to $657.8 million; the TTM figure through Apr 2026 stood at $657.8 million (down 6.85% YoY), while the FY2026 annual figure was $683.1 million, down 2.9% from the prior year.
- Total Liabilities for Q2 2026 stood at $657.8 million, down from $683.1 million in the prior quarter.
- The five-year high for Total Liabilities was $706.2 million in Q2 2025, with the low at $360.3 million in Q2 2022.
- The 5-year median for Total Liabilities is $653.4 million (2024), against an average of $616.8 million.
- The sharpest annual moves came in 2023 and 2026: Total Liabilities jumped 63.27% in 2023, then dropped 6.85% in 2026.
- Exelixis' Total Liabilities stood at $583.1 million in 2022, then increased by 16.36% to $678.4 million in 2023, then increased by 0.95% to $684.9 million in 2024, then fell by 3.21% to $662.8 million in 2025, then retreated by 0.75% to $657.8 million in 2026.
- Business Quant data shows EXEL's Total Liabilities at $657.8 million in Q2 2026, $683.1 million in Q1 2026, and $662.8 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 4.20 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 1.72 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 4.00 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 10.03 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Exelixis | 14.81 Bn | 13.97 Bn | 608.03 Mn | 650.47 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 3, 2026 | 650.47 Mn |
| Apr 3, 2026 | 657.85 Mn |
| Jan 2, 2026 | 683.10 Mn |
| Oct 3, 2025 | 662.85 Mn |
| Jul 4, 2025 | 644.55 Mn |
| Apr 4, 2025 | 706.22 Mn |
| Jan 3, 2025 | 703.49 Mn |
| Sep 27, 2024 | 684.86 Mn |
| Jun 28, 2024 | 653.39 Mn |
| Mar 29, 2024 | 675.74 Mn |
| Dec 29, 2023 | 678.45 Mn |
| Sep 29, 2023 | 629.29 Mn |
| Jun 30, 2023 | 614.53 Mn |
| Mar 31, 2023 | 588.22 Mn |
| Dec 30, 2022 | 583.06 Mn |
| Sep 30, 2022 | 469.97 Mn |
| Jul 1, 2022 | 490.14 Mn |
| Apr 1, 2022 | 360.27 Mn |
| Dec 31, 2021 | 405.62 Mn |
| Oct 1, 2021 | 335.29 Mn |